A meta-analysis of 81 fully reviewed articles reported that most immune-related adverse events of anti-CTLA-4 treatment occur as skin lesions (dermatitis, epidermal spongiosis, and Sweet’s syndrome), hormonal deficiencies, hepatitis, colitis, pancreatic abnormalities, neurologic complications, ocular diseases, visual disturbances, and severe immune complications (51). Here, CTLA4 is linked to sweet syndrome.